• A Pioneer of Developing

    Orphan Drug Business in China

  • Beijing RarePlus MedTech Co., Ltd.


    To fight for the health and to improve the quality of life of many Chinese rare disease patients, RarePlus MedTech (founded in Dec 2015) is positioned as a pioneer in China’s orphan drug areas by devoting to supply economical, effective and safe treatments.


    RarePlus is always patient-centered, and determined to collaborate with all stakeholders along the value chain of rare diseases/orphan drugs, such as physicians, research institutions, patient organizations and so on, for the purpose of providing most advanced quality and systematic medical solutions to Chinese rare disease patients.

    Products & Pipelines


    • Pulmonary Arterial Hypertension Therapies
    • Treatments for Neuroimmune Diseases
    • Treatments for Inherited Metabolic Disorders



    Email: lei.xiao#rareplus.cn (please replace "#" into "@")